Skip to content
Saturday, November 7, 2026
Epic Jackpot House

{‘She lacks no qualifications’: the American scientific field girds for Dr. Høeg's role at the Food and Drug Administration.

As the United States continues making historic changes to its vaccination schedules, one figure has emerged unexpectedly: Dr. Tracy Beth Høeg, a US-based sports physician and public health researcher who initially gained attention by expressing skepticism about coronavirus shots during the pandemic and has focused upon alleged deaths following COVID-19 immunization in her brief time at the Food and Drug Administration.

Scheduled Changes to Pediatric Immunization Program

Health officials planned to announce major revisions to the pediatric vaccine schedule recently, synchronizing the US with the Danish vaccine program, according to reports – a major change that would place the US out of alignment with a large portion of the international standard with little proof for benefit. The planned update has been delayed until the coming year.

Instead of Vinay Prasad, Dr. Høeg is scheduled to present at the event. She was recently named temporary leader of the FDA’s CDER, the fifth appointee to head the center this year.

A Shift at the Regulatory Body

This interim role may indicate a tighter collaboration between the drug and biologics branches as Høeg and Dr. Prasad strengthen their influence at the regulatory agency – and it suggests a renewed priority upon rolling back previously authorized vaccines at the FDA.

Høeg has frequently advocated for ending certain childhood shot schedules in the US to become more like the Danish model, a nation with comprehensive healthcare and a citizenry about the population of Wisconsin’s.

So far comments, she has kept her attention on immunizations – typically the purview of Prasad, head of the FDA’s CBER – instead of medication approval.

Doubts Over Qualifications

Høeg has no apparent track record in medication creation, regulation or leadership, which has been typical for past directors of the Center for Biologics Evaluation and Research. She has served at the FDA as a key advisor to the agency head and CBER since March.

“She appears not to have any of the qualifications” for running the pharmaceutical oversight division, said Jonathan Howard. “She’s never run a scientific study. She has no expertise in managing a major agency. She lacks background in industry regulation.”

Previous commissioners of the center would “be deeply familiar with regulatory frameworks and the research of medication creation”, commented Janet Woodcock. “Frankly, she doesn’t have the sort of resume that previous people who headed the center have had.”

This division has an enormous portfolio at the FDA, she emphasized.

“The public just pays attention on the novel medication approvals, but the generic program clears numerous generic drugs. There’s a biosimilars program, non-prescription drug unit and other areas, and every single one must be supervised,” Woodcock noted. “The responsibility you don’t keep your eye on, that is the part that I always told people is going to bite you.”

Furthermore, a significant administrative element to the job, which manages more than 5,000 personnel. “It’s a enormous management job, if you perform it correctly,” Woodcock added.

Response and Disputed Policies

In response to questions about Dr. Høeg's credentials and whether this selection represents increased cooperation among regulatory chiefs on vaccines, a representative responded that the “concerns stem from incorrect premises”.

“Her experience aligns with the responsibilities of her role,” the official said, citing the time Høeg spent counseling the FDA commissioner on “medication safety and oversight research, including computerized risk analysis and immunization monitoring”.

In her interim role, Dr. Høeg assumes responsibility for the agency head's recently launched fast-track approval initiative, a contentious rapid medication authorization process that reportedly concerned her preceding directors. “By what process are these drugs being chosen for this fast-track system? Who is making the choices?” Dr. Howard asked. “There is a lot of confidentiality happening at the FDA right now.”

Broadly speaking, he stated, “the Food and Drug Administration appears to be shifting towards less stringent oversight of most medications, aside from vaccines.”

Public History on Immunizations

With immunizations, Dr. Høeg has a clearer, if concerning, history, critics have noted. She released a study using non-validated volunteer-provided data to estimate the frequency of heart inflammation following Covid vaccination. She advised the state of Florida top health official Joseph Ladapo, who was said to have changed statistics to imply COVID-19 vaccinations are more dangerous than they are.

Among her “policy goals” for the incoming government included altering rules for recently developed shots and discontinuing “optional” immunizations, she stated after the election on a podcast. At the FDA, Høeg has reportedly floated the idea of barring teenage boys from getting Covid vaccinations.

“She’s an all-around true believer who begins with her preconceived notions and works backwards to fit the data in a extremely misleading, fraudulent fashion,” Dr. Howard stated.

Consolidating Power and a “Campaign of Retribution”

Høeg aligned with other skeptics, {like|

By

Mark Hines

A seasoned casino analyst with over a decade of experience in gaming strategies and jackpot hunting.

Epic Jackpot House

Type to search articles.